Gossamer Bio Stock Performance
| GOSS Stock | USD 1.36 0.06 4.23% |
On a scale of 0 to 100, Gossamer Bio holds a performance score of 14. The company retains a Market Volatility (i.e., Beta) of 1.52, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Gossamer Bio will likely underperform. Please check Gossamer Bio's potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Gossamer Bio's current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Gossamer Bio are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Gossamer Bio unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Caryn Peterson of 18834 shares of Gossamer Bio at 1.36 subject to Rule 16b-3 | 12/31/2024 |
2 | Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 01/07/2025 |
3 | Game-Changing PAH Treatment Combo Shows Powerful Synergistic Effects in Latest Clinical Data - StockTitan | 01/28/2025 |
4 | Vanguard Group Inc Reduces Stake in Gossamer Bio Inc | 01/31/2025 |
5 | Disposition of 6430 shares by Christian Waage of Gossamer Bio at 1.1555 subject to Rule 16b-3 | 02/27/2025 |
6 | With 60 percent ownership of the shares, Gossamer Bio, Inc. is heavily dominated by institutional owners | 03/03/2025 |
7 | Acquisition by Faheem Hasnain of 1540000 shares of Gossamer Bio at 1.13 subject to Rule 16b-3 | 03/04/2025 |
8 | Gossamer Bio GAAP EPS of -0.15 beats by 0.01, revenue of 9.34M beats by 2.32M | 03/13/2025 |
9 | Disposition of 13750 shares by Aranda Richard of Gossamer Bio at 16.4 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 32.1 M |
Gossamer |
Gossamer Bio Relative Risk vs. Return Landscape
If you would invest 84.00 in Gossamer Bio on December 20, 2024 and sell it today you would earn a total of 52.00 from holding Gossamer Bio or generate 61.9% return on investment over 90 days. Gossamer Bio is currently generating 0.9559% in daily expected returns and assumes 5.2902% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Gossamer, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gossamer Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gossamer Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gossamer Bio, and traders can use it to determine the average amount a Gossamer Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1807
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GOSS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.29 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.96 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Gossamer Bio is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gossamer Bio by adding it to a well-diversified portfolio.
Gossamer Bio Fundamentals Growth
Gossamer Stock prices reflect investors' perceptions of the future prospects and financial health of Gossamer Bio, and Gossamer Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gossamer Stock performance.
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (3.85) % | ||||
| Current Valuation | 231.02 M | ||||
| Shares Outstanding | 227.22 M | ||||
| Price To Earning | (4.61) X | ||||
| Price To Book | 10.94 X | ||||
| Price To Sales | 2.81 X | ||||
| Revenue | 114.7 M | ||||
| Gross Profit | 114.7 M | ||||
| EBITDA | (39.97 M) | ||||
| Net Income | (56.53 M) | ||||
| Cash And Equivalents | 304.38 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 202.88 M | ||||
| Debt To Equity | 3.86 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.13 X | ||||
| Cash Flow From Operations | (3.47 M) | ||||
| Earnings Per Share | (0.25) X | ||||
| Market Capitalization | 322.65 M | ||||
| Total Asset | 315.29 M | ||||
| Retained Earnings | (1.27 B) | ||||
| Working Capital | 264.88 M | ||||
| Current Asset | 441.63 M | ||||
| Current Liabilities | 39.84 M | ||||
About Gossamer Bio Performance
Assessing Gossamer Bio's fundamental ratios provides investors with valuable insights into Gossamer Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Gossamer Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (8.65) | (9.08) | |
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.22) | (0.21) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (1.92) | (1.82) |
Things to note about Gossamer Bio performance evaluation
Checking the ongoing alerts about Gossamer Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gossamer Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gossamer Bio is way too risky over 90 days horizon | |
| Gossamer Bio may become a speculative penny stock | |
| Gossamer Bio appears to be risky and price may revert if volatility continues | |
| Gossamer Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 114.7 M. Net Loss for the year was (56.53 M) with profit before overhead, payroll, taxes, and interest of 114.7 M. | |
| Gossamer Bio currently holds about 304.38 M in cash with (3.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Gossamer Bio has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 13750 shares by Aranda Richard of Gossamer Bio at 16.4 subject to Rule 16b-3 |
- Analyzing Gossamer Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gossamer Bio's stock is overvalued or undervalued compared to its peers.
- Examining Gossamer Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gossamer Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gossamer Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gossamer Bio's stock. These opinions can provide insight into Gossamer Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.